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Objective: We evaluated the effectiveness of long acting penicillin (LAP) as a 2-weekly
regimen in winter and a 3-weekly regimen in summer for prevention of streptococcal
colonization and also studied the common complaints of patients during the period of
compliance for LAP administration. We also attempted to determine the incidence of re-
lapses or recurrence of rheumatic fever (RF) after the onset of first episode of RF.
Patients & methods: 210 rheumatic patients with good compliance to LAP (for at least one
year) were included in the study. Demographic, clinical information, patients' complaints
and echocardiographic data of rheumatic patients were collected both retrospectively and
prospectively. Anti-streptolysin O titre (ASOT) and throat swab culture were done at the
end of the study (on Day 14 in the 2-weekly regimen and on Day 21 in the 3-weekly
regimen).
Results: The age of onset of rheumatic fever was mostly between 5 and 15 years and the
youngest patient was 2 years old. Subclinical carditis (SCC) was present in 79 (37%) of all the
patients in the study population. Only 7 patients (3.3%) had a relapse within 2 years of the
acute episode of RF. At the end of the study, ASOT was found to be high only in 11 patients
(5.2%) and throat swab cultures were found negative in all patients
Conclusion: LAP regimen is fairly effective in eradicating streptococcal colonization. The
incidence of relapse of RF within 2 years of the acute episode of RF is relatively low.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
Rheumatic fever (RF) and rheumatic heart disease (RHD) cause
40% of all cardiovascular diseases in developing countries.852.
S.M. Abd El Dayem).
e work, all authors have
ate ethics committees.
ociety of India. All rightsDisability and death from RHD aremainly caused by recurrent
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 7 4 5e7 5 0746Rheumatic fever is a multisystem, immunologically mediated
inflammatory disease, that occurs as a delayed sequel to
group A streptococcal (GAS) infection.2
People with a history of RF are at a high risk of recurrent
attacks and of developing RHD following streptococcal throat
infection. Giving penicillin to these people can prevent
recurrent attacks of RF and subsequent RHD. However, there
is no agreement on the most effective method of giving
penicillin.3
Secondary prophylaxis with benzathine penicillin G (BPG)
is the only scientifically proven strategy to control RHD. It is
recommended to apply a 2-weekly LAP regimen in the first few
years after the acute episode of RF especially in high risk
communities. This can then be followed by a 2-weekly LAP
regimen in winter and a 3-weekly regimen in summers in the
subsequent years. Decisions to stop secondary prophylaxis
should be based on regular clinical assessment.
In this study, we aim to evaluate the effectiveness of long
acting penicillin (LAP) as a 2-weekly regimen inwinter and a 3-
weekly regimen in summer for the prevention of streptococcal
colonization of the throat. Also, we attempted to assess pa-
tients' complaints during the period of compliance for LAP
injections administration and to determine if the second
rheumatic presentation is related to the initial presentation or
not.2. Patients and methods
It is a cross-sectional observational (retrospective and pro-
spective) study conducted after seeking approval from the
local institutional review board and human subjects' protec-
tion. Written consent was obtained from patients and their
parents.
Our study spanned over one year period and included 210
patients who were diagnosed previously with rheumatic fever
according to Jones criteria. All patients reported good
compliance to LAP regimen and regularly attended rheumatic
fever outpatient clinic for a period of at least one year retro-
spective to our study. This was confirmed through a specific
follow-up card maintained for each patient in Rheumatic
Fever Clinic, Cairo University, Children Hospital.
Inclusion criteria:
1. Patients receiving LAP according to their weight (the
regimen of secondary prevention of RF was 600,000 units
LAP for patients weighing 25 kg or less and 1.2million units
for patients weighing more than 25 kg) every 2 weeks in
winter and 3 weeks in summer,4 regardless of age
2. Patient exhibiting good compliance with LAP treatment (for
at least one year).
Exclusion criteria:
1. Patients who developed penicillin allergy during
prophylaxis
2. Patients who refused to continue prophylaxis with LAP
3. Patients on oral penicillin.
Our study had both retrospective and prospective
components.2.1. Retrospective component
It was taken through an organized filing system for each pa-
tient in rheumatic fever clinic and it includes: complaint at
initial attack, history of relapses or recurrence, investigations
done at initial attack (ESR, CRP, ASOT and Echocardiography)
and echocardiography follow up every 3 months. All cases of
relapses were diagnosed in rheumatic fever clinic. The pa-
tients were admitted immediately to Cairo University, Chil-
dren Hospital and were subsequently investigated by one of
the eminent professor of pediatric cardiology who performed
an echocardiography to document the echocardiographic
criteria of relapses. According to the protocol of rheumatic
fever clinic any case of relapse has to be admitted to Cairo
University, Children Hospital in order to be fully investigated
(full labs and echocardiographic imaging).
2.2. Prospective component
Any recent complaint and extensively present medical his-
tory. Anti-streptolysin O titer (ASO Latex test): The plasmatic
ASO Latex test kit for qualitative and semi-quantitative esti-
mation of anti-streptolysin O antibody in human serum was
used. Throat swab culture was done to isolate and identify
group A b hemolytic streptococci. ASOT and throat swab cul-
ture were done at the end of the study (on day 14 in the 2-
weekly regimen and on day 21 in the 3-weekly regimen prior
to receiving the LAP injection) and sensitivity test was also
done for positive culture.
2.3. Echocardiography
Imaging echocardiogram was performed every 3 months and
at the end of the study using standardized protocol with M-
mode, 2-dimensional and pulsed, continuous-wave using
general electric medical echocardiographic machine-model:
vived 7 Pro, GE Vingmed ultrasound AS-N190, HortoneNor-
way equipped with 3 & 7 MHZ transducers.
2.4. Statistical methods
Statistical analysis was conducted using Statistical Package
for Social Science (SPSS) program version 15 (Chicago, Illinois,
USA). Data was summarized as number and percentage.3. Results
Our study included 210 patients with a history of RF (120 on 2-
weekly regimen and 90 patient on 3-weekly regimen). It
included 100 males and 110 females with male to female ratio
of 1:1.1. In our patient cohort, the mean age of onset of RF was
8.0 ± 2.4 years (2e15 years) and the mean patient age was
11.5 ± 2.8 years (4e19 years). Table 1 shows the age of onset of
rheumatic fever of the patients under study. Presenting clin-
ical symptoms of RF included-polyarthritis in 143 patients
(68%), Carditis (clinical and subclinical carditis diagnosed by
echocardiography) in 130 patients (61%), chorea in 14 patients
(6.6%), and Erythema marginatum and subcutaneous nodules
in 1 patient (0.5%) each. 102 out of 210 (48.5%)patients were
Table 1 e Age of onset of rheumatic fever.
Age groups n %
<5 yrs 17 8.1
5e10 yrs 131 62.6
10e15 yrs 60 28.4
15e20 yrs 2 0.9
Table 3 e Echocardiographic findings of rheumatic
patients included in the study.
Variables n %
Mitral valve thickness 160 76
Mitral regurgitation 168 80
Mitral stenosis 6 2.8
Aortic valve thickness 6 2.9
Aortic regurgitation 56 27
Aortic stenosis 2 1
Pericardial effusion 1 0.5
Pulmonary artery pressure
Normal 110 52.1
Elevated 87 41.2
Undetermined 14 6.6
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 7 4 5e7 5 0 747anemic (Hb% < 11.5 g/dl) at presentation, 19% patients had
cardiomegaly, 19.9% had thrill and 58.8% had apical systolic/
basal diastolic murmur. 54 (25.7%) patients complaint of sore
throat but on examination, only 19 cases (9%) were found to
have pharyngitis. 46.4% patients complaint of arthralgia but
on examination only 0.5% had arthritis. Rheumatic arthritis in
the first attack was found in 68% of the studies patients.
Systems affected during the period of the study are shown in
Table 2. Echocardiographic finding of rheumatic patients at
the end of the study is shown in Table 3.
In our study, 7 patients (3.3%) had relapse within the first 2
years after acute episode of RF. 4 patients (75%) had relapse in
the form of arthritis, 1 patient (14.2%) had carditis and 2 pa-
tients (28.5%) had chorea. Demographic and clinical data of
patients with relapses are shown in Table 4. ASOT of rheu-
matic patients at the end of the study was >200 todd U/ml in
11 (5.2%) patients. Throat swab cultures of all patients were
negative.4. Discussion
In our study, age of onset of rheumatic fever was between 5
and 15 years for 91% of the patients and between 5 and 10
years for 62.6% patients. This agreed with the study done by
Omokhodion et al and Mahmudi et al, who reported that 70%
of patients had age at onset of RF between 5 and 15 years.5,6
This age distribution coincides with the peak incidence of
streptococcal infection in children.7Table 2 e Systems affected during the period of the study
of patients included in the study.
Variables n %
Articular affection
Arthralgia 98 46.7
Arthritis 1 0.5
Cardiac affection
Chest pain 37 17.6
Dyspnea 52 24.8
Exercise intolerance 105 50.0
Neuropsychiatric manifestation
Abnormal movements during regimen 7 3.3
Emotional labiality during regimen 5 2.4
Respiratory manifestation
Pharyngitis 19 9
Nares excoriatum 42 20.0
Wheezes 14 6.7
Crepitations 64 30.5
Gastrointestinal
Hepatomegaly 3 1.4
Urological manifestation
Loin tenderness 20 9.5Seventeen of our patients (8.1%) had age of onset of RF
below 5 years (the youngest was 2 years old). This agreed with
the study done by Yee et al, who reported rheumatic carditis
in the first year of life.8 Also, Seckeler et al, found that age at
diagnosis of RF ranged from 2.9 to 17.1 years (median 10.6
years).9
In our study, initial presentation of RF was in the form of:
143 patients (68%) had polyarthritis, 130 patients (61%) had
carditis (clinical and subclinical diagnosed by echocardiogra-
phy), 14 patients (6.6%) had chorea, 1 patient (0.5%)had ery-
thema marginatum and 1 patient (0.5%) had subcutaneous
nodules. This coincides with Seckeler et al, who reported that
fever and carditis were the most common presenting
findings.9
Rheumatic fever (RF) is usually preceded by Group A b he-
molytic streptococci (GAbHS) of the upper respiratory tract. A
history of earlier sore throat (32%) was reported by Mahmoud
et al,10 while in Omran andMourad11 the percentage was little
lower (29.3%). In our study, 54 patients (25.7%) complained of
sore throat while on examination pharyngitis was detected
only in 19 cases (9%). This is also confirmed by Carapetis
et al,12 who noted that the symptoms of acute pharyngitis are
more often caused by viruses (adenoviruses, enteroviruses
and influenza viruses) than by Group A Streptococcal (GAS).
Differentiation of GAS pharyngitis from viral pharyngitis
based on history and clinical findings is difficult. Even expe-
rienced clinicians are unable to differentiate streptococcal
pharyngitis from pharyngitis caused by other pathogens.12
In our study population, the most common articular
manifestation during the compliance period of LAP injections
was in the form of arthralgia, which presented in 46.7% pa-
tients. However, only 0.5% of the patients had clinical signs of
arthritis on examination. This small incidence of clinical
arthritis may be due to the other causes of arthritis such
as post-streptococcal reactive arthritis associated with strep-
tococcal infections. Because of difficulties in differentiating
this kind of arthritis from that of acute rheumatic fever (ARF),
this condition should rarely, if ever, be diagnosed in high risk
populations.12 Carapetis et al,12 suggested that in recurrent
attack of ARF in high risk groups, polyarthritis or aseptic
monoarthritis or polyarthralgia should form a major criterion
for diagnosis. Rayamajhi et al also proposed that arthralgia
should be changed from a minor to a major criterion.13
Similarly, the common cardiac symptoms during the
period of our study included chest pain in 37 (17.6%) patients,
Table 4 e Demographic and clinical data of patients with relapses.
Serial no
of relapse
Age of onset
of RF (yrs)
Age of
patients (yrs)
Time from
1st attack till
relapse (yrs)
Form of
1st attack
Form of relapse Duration of
regimen at
relapse (WK)
Recent ASOT
Todd U/ml
1 8 9 1 Polyarthritis Monoarthritis 3 <200
2 5 12 2 Polyarthritis Chorea 3 400
3 9 13 2 Polyarthritis Carditis 2 <200
4 4.5 6.5 1 Polyarthritis Polyarthritis 2 <200
5 11.5 17 1.5 Polyarthritis Polyarthritis 3 <200
6 10 13 2 Polyarthritis Polyarthritis 3 <200
7 9 12.5 1.5 Polyarthritis Chorea, carditis 3 <200
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 7 4 5e7 5 0748dyspnea in 52 (24.8%) patients and exercise intolerance in 105
(50.0%) patients. Dyspnea and exercise intolerancemay be due
to the fact that 102 of the studied patients (48.5%) were anemic
(HB% <11.5 g/dl). Regarding cardiac signs, on clinical exami-
nation 19% patients had cardiomegaly, 19.9% had thrill and
58.8%had apical systolic/basal diastolicmurmur. In our study,
rheumatic carditis (evident clinically and sub-clinically as
diagnosed by echocardiography) was detected in a total of 130
(61%) out of 210 studied cases. Evident clinical carditis at 1st
presentation was detected in 51 (24.3%) of all studied patients
while subclinical carditis (clinical examination is normal but
echocardiogram is abnormal) was found in 79 (37%) of all
studied patients.14
In a study by Figuerora et al, to determine the frequency of
occurrence and long term evolution of subclinical carditis in
patients with ARF, it was found that during an episode of RF
and also during follow up, Doppler echocardiography detected
more valvular lesions than clinical examination. In this study,
25 of 35 rheumatic patients (71% of studied patients) had
echocardiographic evidence of valvular (mitral or aortic)
incompetence at the time of entry into study. On the other
hand, in 10 out of 35 patients (30% of all the RF patients
entering the study), no auscultatory or clinical findings sug-
gestive of acute rheumatic carditis could be found despite
repeated examinations. These 10 individuals constituted the
group of rheumatic fever patients with subclinical carditis.15
Khriesat and Najada, found four cases (25%) with silent
carditis which were established after echocardiography.16
This finding shows it is important to repeat echocardiogra-
phy over the period of next 3e4 weeks because the valvular
involvement which was absent in the beginning may appear
later. This validates that echocardiography results are the
major criterion for diagnosis of ARF. The diagnosis of silent
carditis was established only after echocardiography. These
findings highlight the importance of repeating echocardiog-
raphy over the next 3e4 weeks, as valvular involvement
which was absent initially, may appear later, supporting the
view, that echocardiographic findings should be considered as
a major criterion for diagnosis of ARF.15 According to Car-
apetis et al, echocardiography results showing subclinical
valve damage will help skilled clinicians to diagnose ARF and
confirm the presence of carditis in cases of ARFwithout a clear
pathological heart murmur. Therefore, it is important to
include diagnosis of echocardiographically suggested valve
damage as themajormanifestation in patients with ARF/RHD.
Echocardiographic diagnosis of subclinical valve damage can
help experienced clinicians inmaking the diagnosis of ARF, orin confirming the presence of carditis in cases of ARF without
an obviously pathological heart murmur. Therefore, they
recommended that echocardiographically suggested valve
damage (subclinical or otherwise), diagnosed by a clinician
with experience in echocardiography of patients with ARF/
RHD, be included as a major manifestation.12
Mitral regurgitation (MR) was found to be the most com-
mon valve affection in our study and was diagnosed by
echocardiography at the end of the study. MR was evident in
80% of cases, a figure close to findings byMahmudi et al,6 from
Iran, who reported that mitral regurgitation was present in
75% of rheumatic patients. Another study revealed that MR
was the most common lesion in the first and second decades
of life.17 Pereira et al also noticed that MR was the most
commonly occurring lesion in ARF.18 The rates of mitral valve
repair for RHD are currently greater than 90% in the children's
cardiac unit but remain low in adult cardiac units in New
Zealand.19 In our study, Aortic regurgitation (AR) was the
second most often affected cardiac valve. It was evident in
27% of cases, a finding similar to that of Biter et al from Leb-
onan, who found the incidence of AR among rheumatic pa-
tients to be close to 35%.However, this finding was in contrast
to that of Omran et al who reported the incidence of AR in
rheumatic patients to be 52%.20
As regards neuropsychiatric manifestations, 4.3% patients
complained of abnormal movement and 3.8% of behavior
abnormalities during the period of our study. On examination
3.3% patients had abnormal movements and 2.4% had
emotional disability during their period of compliance with
LAP injections. Chockalingam et al found chorea in only 4% of
their total study population of acute rheumatic patients.21
This small number of such cases may be due to other causes
of chorea, because pediatric autoimmune neuropsychiatric
disorders are also associated with streptococcal infections.
However, due to the difficulties in differentiating chorea from
ARF, this condition should not be suspected, especially in low-
risk populations.12
In our study, 7 patients (3.5%) had relapsese 3 patients had
polyarthritis, 1 patient had monoarthritis, 1 patient had car-
ditis and 2 patients had chorea. Four of these seven patients,
who had relapse in form of arthritis, also had arthritis as their
initial presentation. The remaining 3 patients had different
form of relapse from their original manifestation. Oran et al
reported that, the recurrences were associated with more
severe damage to organs, particularly the heart, which may
have been injured during the initial attack.22 Relapse occurs
within the first 2 years of the acute episode of RF (3 patients
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 7 4 5e7 5 0 749after 2 years, 2 patients after 1.5 years, and 2 patients after
1 year).
American Heart Association (AHA) recommended 3-
weekly regimen of LAP in countries where incidence of
rheumatic fever is particularly high. However, some authors
have recommended 2-weekly regimen. These recommenda-
tions are in agreement with findings from our study-out of the
7 patients who had relapse, 5 were on the 3-weekly regimen of
LAP, while 2 were on the 2-weekly regimen of LAP. This in-
dicates the effectiveness of LAP in prevention of repeated at-
tacks of RF. Oran et al suggested that the interval between
injections should be 15 days during the first 2 years after the
acute episode of RF and 21 days during the subsequent years.22
Manyemba andMayosi reported that penicillin reduces the
risk of recurrence of RF by 55% and that of streptococcal throat
infections by 16%.3 On the contrary, Seckeler et al reported the
recurrence rate of RF in penicillin treated group as 38%.9
An individual who had already suffered an attack of RF is
more prone to develop a recurrence following GAS pharyn-
gitis. To prevent such recurrences, these people must be
administered continuous antimicrobial prophylaxis. The
duration of prophylaxis is determined based on the number
of previous attacks; time elapsed since the last attack, age of
the patient, any cardiac involvement and risk of exposure to
GAS infections. Penicillin is the drug of choice for secondary
prophylaxis among such cases, but in penicillin-sensitive
patient sulfadiazine, macrolide or azalide may also be
considered.4
A rather low incidence of relapse in our study reflects the
effectiveness of giving LAP as a 2-weekly regimen in winter
and a 3-weekly regimen in summer. This finding also cor-
roborates with a recent systematic review which compared
2e3 weekly LAP treatment with 4-weekly IM penicillin in pa-
tients with earlier attacks of RF. One trial was done, showing
that the 2 or 3 weekly injections were more effective than 4-
weekly injections in preventing RF recurrences. Evidence of
the trial shows 2-weekly injections results in almost 50%
reduction in RF recurrences and 40% decrease in streptococcal
throat infections as compared to 4-weekly injections. How-
ever, the evidence for 3-weekly injections is comparatively
less stronger if the systematic error by inadequate randomi-
zation in the study is taken into account.3,12
Another study was done in Brazil to evaluate penicillin
concentrations in sera at 1, 10, 14, and 21 days after IM in-
jections of benzathine penicillin G (BPG) 40,000 IU/kg. The
minimum recommended serum penicillin concentrations in
order to prevent recurrence of RF is 0.02 mg/ml. This study
revealed that themean serum penicillin concentration after 1,
10, 14 and 21 days of drug administration was 0.08, 0.03, 0.02
and 0.01 micro gm/ml respectively. This means that in a ma-
jority of children, by week 3 of administration, serum peni-
cillin concentration becomes inadequate for prevention of RF
in a majority of children.23 According to pharmacokinetic
studies, the concentration of penicillin in serum remains
above the minimum inhibitory levels when penicillin in-
jections are given every 2 weeks. So, the above results support
a 2-weekly regimen.3
In our study, at the time of relapse, one relapsed patient
had ASOT equal 400 todd U/ml, while the remaining 6 patients
had recent ASOT less than 200 todd U/ml. The results of allthroat swab cultures of the studied patients were negative.
This proves the effectiveness of a 2-weekly regimen in winter
and a 3-weekly regimen in summer for eradicating strepto-
coccal colonization in the throat. However, this raises an
important questionewhy did 7 patients had relapse, while all
of them had negative throat cultures? This can partly be
explained by the fact that the throat cultures in our studywere
only done for Group A streptococcal infections and not for
other groups such as C, G, F and B. Many other researchers
have had similar findings in the past. In 2001, researchers
studied the streptococcal carriage rate in throat among the
public school children in Nigeria and found the carriage rate to
be 13.3%. Another study found the streptococcal carriage rate
of 9.78% without any Lance field group A isolates. However,
the incidence of streptococcal groups C, G, F and B carrierswas
found to be 38%, 36%, 20%, and 7% respectively.
Non-group A streptococci are more dominant in tropical
and subtropical countries, therefore its very likely that a larger
no of patients develop RF secondary to non-group A b hemo-
lytic streptococci. In fact, scientists have suggested a stronger
role of groups C and G b hemolytic streptococci in humans
with non-suppurative sequelae in the tropical and subtropical
countries, where the prevalence of RF/RHD is high.5 Dinkla
et al also suggested that the streptococcal strains causing ARF
form an auto antigenic complex with human collagen IV.
Pharyngeal carriage of group C and G streptococci prevails in
some geographical regions witnessing high incidence of ARF.
M-like surface proteins that bind to human collagen have
been identified on the surface of group C and G streptococci.
Therefore, it advisable to eradicate streptococci that possess
collage binding proteins to prevent recurrent of RF.24
On the other hand, we found that only 11/210 (5.2%) pa-
tients had recent ASOT >200 todd U/ml after compliance LAP
regimens at least for one year. This reflects the effectiveness
of LAP regimen in lowering ASOT value and prevention of
streptococcal colonization of the throat. This raises the
question about why 11 patients still has high ASOT in our
study while all throat cultures were negative. This can be
explained by the fact that there are other causes that raises
ASOT, as in certain related diseases such as rheumatoid
arthritis, familial Mediterranean fever, Takayasu's arteritis
and streptococcal impetigo.25
Limitation of the study:
1. Longer term follow-up study is difficult to do.
2. Serum level of penicillin was not evaluated due to un-
availability of the kits in our country.
3. No control group was included due to refusal of non-
compliant patients for follow up.
We concluded that age of onset of rheumatic fever was
mostly between 5 and 15 years and the youngest age was 2
years. Polyarthritis was the most common presentation of RF
followed by carditis. Subclinical carditis was present in 79
patients (37%) of all studied patients. MR was the most com-
mon lesion followed by aortic regurgitation. Rate of relapse of
RF is low and it happens within 2 years after the acute episode
of RF. LAP is effective for eradication of streptococcal coloni-
zation in the throat. Secondary prophylaxis with LAP is shown
to be the only effective RHD control strategy.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 7 4 5e7 5 0750We recommend applying the 2-weekly LAP regimen in the
first few years after the acute episode of RF especially in high
risk communities. Then, during the subsequent years, a 2-
weekly LAP regimen in winter and a 3-weekly regimen in
summer, appeared to be very effective. We also advise
monthly cardiac follow up and routine serial echocardiogra-
phy for the early detection andmanagement of complications.
Aggressive follow up also helps make timely decisions
regarding withdrawal of secondary prophylaxis.Conflicts of interest
All authors have none to declare.r e f e r e n c e s
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